Bing Hou

Therapeutic preclinical study on the synergy between CD73 inhibitors and selinexor for managing multiple myeloma

Chunli Zhang, Qiuxia Wei, Gang Bian, Chaoling Wu et autres

cn (code pays fourni par la source)

Intraventricular metastasis with malignant progression of an intraspinal solitary fibrous tumor: a case report and review of the literature

Zhiwang Guo, Xiaolei Chen, Huimin Chang, Bing Hou

cn (code pays fourni par la source)

Abstract 3509: ATG-110, a novel “2+1” LY6G6D-targeted T-cell engager (TCE) for the treatment of MSS colorectal cancer

Gang Bian, Jiahui Hua, Ge Lin, Xueli Chen et autres

cn (code pays fourni par la source)

Abstract 4230: Preclinical characterization of ATG-042, a novel MTAP null-selective PRMT5 inhibitor

Ya Kong, Ge Lin, Ming Zhang, Peng Chen et autres

cn (code pays fourni par la source)

Abstract 7326: ATG-201, a novel T-cell engager (TCE) effectively depletes B cells with reduced risk of CRS for the treatment of B cell malignancies and B cell related autoimmune diseases

Gang Bian, Huiling Liu, Tengteng Li, Zaoshun Hu et autres

cn (code pays fourni par la source)

Abstract 671: Development of a diagnostic antibody for CD24 targeted therapy

Peng Chen, Jishun Chen, Min Deng, Rong Guo et autres

cn (code pays fourni par la source)

A randomized double-blind placebo-controlled clinical trial on the efficacy and safety of herbal medicine San-jia-fu-mai (SJFM) in the treatment of atrial fibrillation and heart failure with preserved ejection fraction (yin depletion syndrome)

Yang Yang, Sizhao Li, Yujie Liu, Yunhu Song et autres

Coated proppants with self-suspension and potassium permanganate slow-release functions

Quan Xu, Dechen Zhang, Siyuan Chen, Jialun Luo et autres

cn, pl (code pays fourni par la source)

1067 ATG-201, a novel ‘2+1’ CD19-targeted T-cell engager (TCE) for the treatment of B cell malignancies and B cell related autoimmune diseases

Gang Bian, Huiling Liu, Tengteng Li, Zaoshun Hu et autres

cn (code pays fourni par la source)

1069 ATG-106, a novel ‘2+1’ format CDH6-targeted T-cell engager (TCE), shows potent T cell dependent cytotoxicity and in vivo anti-tumor efficacy

Tengteng Li, Peng Chen, Huiling Liu, Zaoshun Hu et autres

cn (code pays fourni par la source)

Abstract 4592: Preclinical characterization of ATG-042-198, a novel MTAP null-selective PRMT5 inhibitor

Ya Kong, Ming Zhang, Lulu Jiang, Ruiting Xu et autres

cn (code pays fourni par la source)

Abstract 6343: AnTenGagerTM, a novel “2+1” T cell engager platform, enables conditional T cell activation with reduced risk of CRS

Bing Hou, Hui Yuwen, Tengteng Li, Yijing Ren et autres

us (code pays fourni par la source)